CHINYERE NZEKWE: Open Payments
NPI 1487235172 · LAUREL, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,135 in 57 payments from 12 companies in 2025. Trend: 2023 $263 · 2024 $707 · 2025 $2,135
Food & beverage: $2,135
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 7 | $518 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 12 | $295 |
| Neurocrine BioSciences, Inc. | 2 | $254 |
| ABBVIE INC. | 10 | $226 |
| Supernus Pharmaceuticals, Inc. | 8 | $222 |
| E.R. Squibb & Sons, L.L.C. | 3 | $222 |
| Alkermes, Inc. | 5 | $172 |
| Lundbeck LLC | 4 | $78 |
| Janssen Scientific Affairs, LLC | 1 | $58 |
| Axsome Therapeutics, Inc. | 2 | $43 |
Products named: REXULTI, CAPLYTA, INGREZZA, VRAYLAR, Qelbree, COBENFY, ARISTADA, INVEGA SUSTENNA.
Industry payments across MD — which companies pay providers there.
